VIP: Risks & Legal Status
Important safety information, risks, and regulatory status
Important Safety Warnings
- Cardiovascular risk from potent vasodilation: VIP is among the most potent endogenous vasodilators known. Systemic administration produces dose-dependent hypotension through direct smooth muscle relaxation and endothelium-dependent NO release. Severe hypotension can result in syncope, organ hypoperfusion, and cardiovascular collapse, particularly in patients with impaired cardiovascular reserve or those taking concurrent antihypertensive or vasodilatory medications.
Mitigation: Continuous hemodynamic monitoring during any IV administration. Dose escalation protocols with defined blood pressure thresholds for dose reduction or cessation. Avoidance in patients with severe hypotension or decompensated heart failure.
- No approved pharmaceutical formulation: VIP (aviptadil) has not received regulatory approval from the FDA, EMA, or any other regulatory authority for any therapeutic indication. There is no commercially available pharmaceutical-grade formulation with established manufacturing standards, quality control, potency verification, or sterility assurance. Research-grade VIP obtained from chemical suppliers may vary in purity, potency, endotoxin content, and formulation.
Mitigation: Use only in institutional research settings with appropriate regulatory oversight (IND, ethics committee approval). Source peptide from reputable suppliers with certificate of analysis including purity (HPLC), identity (mass spectrometry), and endotoxin testing.
📌TL;DR
- •5 risk categories identified
- •2 high-severity risks
- •Legal status varies by country (4 countries listed)
Risk Assessment
VIP is among the most potent endogenous vasodilators known. Systemic administration produces dose-dependent hypotension through direct smooth muscle relaxation and endothelium-dependent NO release. Severe hypotension can result in syncope, organ hypoperfusion, and cardiovascular collapse, particularly in patients with impaired cardiovascular reserve or those taking concurrent antihypertensive or vasodilatory medications.
Mitigation: Continuous hemodynamic monitoring during any IV administration. Dose escalation protocols with defined blood pressure thresholds for dose reduction or cessation. Avoidance in patients with severe hypotension or decompensated heart failure.
VIP (aviptadil) has not received regulatory approval from the FDA, EMA, or any other regulatory authority for any therapeutic indication. There is no commercially available pharmaceutical-grade formulation with established manufacturing standards, quality control, potency verification, or sterility assurance. Research-grade VIP obtained from chemical suppliers may vary in purity, potency, endotoxin content, and formulation.
Mitigation: Use only in institutional research settings with appropriate regulatory oversight (IND, ethics committee approval). Source peptide from reputable suppliers with certificate of analysis including purity (HPLC), identity (mass spectrometry), and endotoxin testing.
VIP has a circulating half-life of only 1-2 minutes due to degradation by NEP, DPP-IV, and aminopeptidases. This extremely rapid clearance means that achieving and maintaining therapeutic concentrations requires continuous IV infusion or specialized delivery systems. Bolus dosing produces only transient effects, and even continuous infusion may not achieve sufficient tissue concentrations at target sites such as the pulmonary vasculature or CNS.
Mitigation: Continuous infusion protocols for systemic delivery. Inhaled delivery for pulmonary targets. Investigation of protease-resistant analogs, PEGylation, or nanoparticle encapsulation for sustained-release approaches.
No studies have evaluated the safety of chronic or repeated VIP administration in humans. As a pleiotropic neuropeptide involved in immune regulation, circadian rhythms, cell proliferation, and neuroendocrine function, the long-term consequences of exogenous VIP exposure are entirely unknown. Theoretical risks include impaired immune surveillance, effects on tumor biology, and disruption of circadian or neuroendocrine homeostasis.
Mitigation: Currently no mitigation available due to absence of long-term data. Any extended-use research protocol should include comprehensive safety monitoring of immune, endocrine, and oncologic parameters.
VIP activates both VPAC1 and VPAC2 receptors with similar affinity. Because these receptors mediate distinct and sometimes opposing effects in different tissues, the inability to selectively target one receptor subtype limits therapeutic precision. Desired VPAC1-mediated immune modulation is accompanied by VPAC2-mediated effects on smooth muscle, metabolism, and other systems, contributing to off-target effects.
Mitigation: Development of receptor-selective VIP analogs is an active area of research. Clinical protocols should account for multi-receptor activation when assessing benefit-risk profiles.
⚠️Important Warnings
- •VIP is an investigational compound with no regulatory approval for any therapeutic use. All information in this article is for educational and research reference purposes only.
- •Intravenous VIP administration can cause clinically significant hypotension and requires continuous hemodynamic monitoring in a supervised clinical environment. Self-administration outside a clinical setting poses serious cardiovascular risks.
- •Research-grade VIP products are not manufactured to pharmaceutical standards and may contain impurities, endotoxins, or degradation products that could cause adverse reactions. These products are intended for laboratory research only.
- •No long-term safety data exist for VIP in humans. The consequences of chronic or repeated exposure on immune function, tumor biology, endocrine regulation, and circadian rhythms are unknown.
- •VIP should not be used during pregnancy due to its roles in reproductive biology and the absence of reproductive safety data.
- •Patients with cardiovascular disease, hypotension, or heart failure are at elevated risk of adverse hemodynamic effects from VIP and should not receive this compound outside of closely monitored research protocols.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Unregulated | VIP (aviptadil) is not a controlled substance and is not FDA-approved for any indication. It is available as a research chemical. The ZYESAMI (aviptadil) EUA application for COVID-19 was submitted but not granted. VIP may be used in clinical research under an Investigational New Drug (IND) application. |
| European Union | Unregulated | VIP is not approved by the EMA for any therapeutic indication. It is available as a research reagent and may be used in clinical trials under appropriate regulatory authorization from national competent authorities. No centralized marketing authorization has been granted or sought. |
| United Kingdom | Unregulated | VIP is not approved by the MHRA for any therapeutic indication. Available for research use. Clinical investigation requires appropriate regulatory approval. |
| Australia | Unregulated | VIP is not listed on the Australian Register of Therapeutic Goods (ARTG). Available for research use. Clinical use would require TGA authorization through the Clinical Trial Notification or Clinical Trial Approval scheme. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 60+ community reports
View community protocolsCritical Safety Information#
Vasoactive Intestinal Peptide (VIP) is an investigational research compound that has not been approved by any regulatory authority for therapeutic use in humans. The risk information presented in this article is derived from pharmacological studies, clinical trial data, and the known biology of VIP and its receptor systems. This information is intended for educational and research reference purposes. Any use of VIP outside of properly authorized and supervised research settings carries significant and potentially life-threatening risks.
Primary Risk Categories#
Cardiovascular Risk: Hypotension#
The most serious and immediate risk of systemic VIP administration is hypotension. VIP ranks among the most potent endogenous vasodilators identified in mammals, producing dose-dependent reductions in systemic vascular resistance through multiple mechanisms. These include direct cAMP/PKA-mediated relaxation of vascular smooth muscle, endothelium-dependent vasodilation through eNOS activation and nitric oxide release, and potassium channel activation leading to smooth muscle membrane hyperpolarization.
The hypotensive response to VIP is rapid in onset, dose-dependent, and can be clinically severe. In the ZYESAMI clinical trial for COVID-19 respiratory failure, hypotension was a commonly observed adverse event requiring dose adjustment or discontinuation. The reflex tachycardia triggered by VIP-induced hypotension can increase myocardial oxygen demand and may pose additional risks in patients with coronary artery disease.
The severity of this risk is compounded by VIP's extremely short half-life, which creates a steep relationship between infusion rate and plasma concentration. Small changes in infusion rate can produce disproportionate changes in blood pressure, making precise dose titration essential. Concurrent use of antihypertensive medications, vasodilators, or agents that blunt the baroreceptor reflex (such as beta-blockers) can potentiate the hypotensive effect to dangerous levels.
Absence of Approved Formulations#
VIP has no approved pharmaceutical formulation from any regulatory authority worldwide. The clinical formulation used in the ZYESAMI trial (aviptadil) was manufactured under investigational product standards for trial use only and is not commercially available. VIP obtainable from research chemical suppliers is produced for laboratory research purposes and does not meet the manufacturing, quality control, and safety standards required for human pharmaceutical products.
Research-grade VIP products may vary significantly in purity (peptide content, identity confirmation), sterility (absence of microbial contamination), endotoxin levels (bacterial lipopolysaccharide, which can trigger severe inflammatory reactions), stability (degradation products), and formulation (counterions, excipients, pH). The use of such products in human subjects outside of regulated clinical trials poses unpredictable risks from both the active peptide and from contaminants or degradation products.
Rapid Enzymatic Degradation#
VIP's circulating half-life of approximately 1-2 minutes represents both a safety feature (rapid offset of adverse effects) and a significant efficacy risk. The rapid degradation by NEP, DPP-IV, and other peptidases means that conventional routes of administration (subcutaneous injection, oral ingestion) are essentially ineffective for achieving systemic therapeutic concentrations. Even continuous intravenous infusion may not achieve adequate tissue concentrations at target sites such as the pulmonary vasculature (in PAH) or the central nervous system (in neurodegeneration).
This pharmacokinetic limitation has been the primary barrier to clinical translation of VIP's extensive preclinical efficacy data. The failure of the controlled PAH trial and the ZYESAMI COVID-19 trial may be at least partly attributable to insufficient drug delivery to target tissues despite measurable systemic effects.
Unknown Long-Term Safety#
The absence of chronic administration safety data represents a fundamental gap in VIP's risk profile. VIP participates in numerous physiological systems, and the consequences of sustained exogenous exposure are theoretically concerning in several domains:
- Immune surveillance: VIP is a potent anti-inflammatory and immunosuppressive agent. Chronic VIP exposure could theoretically impair immune surveillance mechanisms, potentially increasing susceptibility to infections or reducing the immune system's capacity to detect and eliminate malignant cells.
- Tumor biology: VPAC1 and VPAC2 receptors are expressed on various cancer cell types, including lung, breast, prostate, and gastrointestinal cancers. The literature contains conflicting reports regarding VIP's effects on tumor cell proliferation, with some studies suggesting growth promotion and others indicating growth inhibition depending on cancer type and receptor expression. This unresolved question represents a meaningful risk in the context of chronic VIP exposure.
- Circadian disruption: VIP is essential for maintaining synchrony among suprachiasmatic nucleus oscillator neurons. Exogenous VIP administration could potentially disrupt circadian rhythm regulation, with downstream consequences for sleep, metabolism, hormone secretion, and cognitive function.
- Neuroendocrine effects: VIP modulates the release of multiple hormones, including prolactin, growth hormone, and insulin. Chronic VIP exposure could alter neuroendocrine axes in unpredictable ways.
Regulatory and Legal Status#
VIP (aviptadil) is not classified as a controlled substance in any major jurisdiction. It is categorized as an unregulated research compound in the United States, European Union, United Kingdom, and Australia. This means that while possession and purchase for research purposes is generally legal, the compound has no approved therapeutic use and cannot be legally marketed, prescribed, or dispensed as a medicine.
In the United States, VIP can be legally used in clinical research under an Investigational New Drug (IND) application filed with the FDA. The ZYESAMI trial operated under such an IND. Outside of IND-authorized trials, clinical use of VIP in humans does not have regulatory sanction. The FDA's denial of the Emergency Use Authorization application for aviptadil in COVID-19 further underscores the absence of regulatory confidence in the compound's efficacy and safety profile for clinical use.
| Jurisdiction | Regulatory Status | Approved Indications | Research Use | Clinical Trial Requirements |
|---|---|---|---|---|
| United States | Not FDA-approved; not a controlled substance | None | Legal as research chemical | IND application required |
| European Union | Not EMA-approved; not controlled | None | Legal as research reagent | National competent authority approval |
| United Kingdom | Not MHRA-approved; not controlled | None | Legal for research | MHRA regulatory approval |
| Australia | Not on ARTG; not controlled | None | Legal for research | CTN or CTA via TGA |
Specific Warnings#
Self-Administration Risks#
VIP is not a compound that can be safely self-administered outside of a clinical environment. The potent vasodilatory effects require continuous blood pressure monitoring and the immediate availability of resuscitative measures. Unlike many peptides investigated in the wellness and performance optimization space, VIP carries a significant risk of acute cardiovascular collapse at doses that are difficult to control without intravenous infusion pumps and hemodynamic monitoring equipment. Attempting to self-administer VIP by any route carries serious and potentially fatal risks.
Drug Interactions#
Patients taking antihypertensive medications (including ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, beta-blockers, and diuretics) face an elevated risk of severe hypotension if exposed to VIP. Concurrent use of nitrates, phosphodiesterase-5 inhibitors, or prostacyclin analogs presents particular danger due to synergistic vasodilation. These interactions are not theoretical; they follow directly from the known pharmacology of each drug class and the established mechanism of VIP-induced vasodilation.
Vulnerable Populations#
The following populations are at elevated risk from VIP exposure and should not receive the compound outside of carefully controlled research settings with full informed consent:
- Patients with cardiovascular disease: Underlying coronary artery disease, heart failure, or arrhythmias may be exacerbated by VIP-induced hemodynamic changes.
- Elderly individuals: Age-related reductions in cardiovascular reserve and baroreceptor sensitivity may amplify the hypotensive response.
- Pregnant women: VIP has documented roles in uterine blood flow regulation, embryo implantation, and placental function. Exogenous VIP during pregnancy could disrupt reproductive processes, and no reproductive safety studies have been conducted.
- Immunocompromised patients: VIP's immunosuppressive properties could further impair immune function in already immunocompromised individuals.
Risk-Benefit Assessment#
The current risk-benefit assessment for VIP is unfavorable for clinical use. The risks are concrete, immediate, and well-characterized (hypotension, absence of quality-controlled formulations, rapid degradation limiting efficacy). The potential benefits, while biologically plausible and supported by preclinical evidence, have not been confirmed in adequately controlled human trials. Both of the most advanced clinical programs (PAH and COVID-19) failed to meet their primary efficacy endpoints, while the adverse effect profile remained as expected from the compound's pharmacology.
Until one of the following developments occurs, VIP's risk-benefit profile is unlikely to shift favorably: the development of a long-acting, receptor-selective VIP analog with an improved therapeutic window; the identification of a targeted delivery method that achieves therapeutic tissue concentrations without systemic vasodilation; or the completion of a well-powered, randomized controlled trial demonstrating clear efficacy for a specific indication. Active research in all of these areas is ongoing.
Related Reading#
Frequently Asked Questions About VIP
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.